The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $59.30

Today's change+0.40 +0.68%
Updated July 22 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $59.30

Today's change+0.40 +0.68%
Updated July 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Spdr S&P Biotech Etf Hits New 20-day High

Spdr S&P Biotech Etf closed up Friday by (U.S.)$0.40 or 0.68% to (U.S.)$59.30 and setting a new 20-day high. Over the last five days, shares have gained 3.80%, but are down 15.53% for the last year to date. Shares have underperformed the S&P 500 by 36.38% during the last year.

Key company metrics

  • Open(U.S.) $59.13
  • Previous close(U.S.) $58.90
  • High(U.S.) $59.68
  • Low(U.S.) $58.60
  • Bid / Ask-- / --
  • YTD % change-15.53%
  • Volume4,262,362
  • Average volume (10-day)5,840,463
  • Average volume (1-month)7,473,213
  • Average volume (3-month)7,374,319
  • 52-week range(U.S.) $44.16 to (U.S.) $90.14
  • Beta1.42
  • Trailing P/E3.25×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.45
  • Dividend yield0.76%
  • Trailing EPS(U.S.) $18.23
Updated July 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,202.84%

Based on its net profit margin of 2,202.84%, Spdr S&P Biotech Etf is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.24%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q4/2014Q2/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Jun 30, 201406/30/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013
Revenue81032
Total other revenue--------
Total revenue81032
Gross profit--------
Total cost of revenue--------
Total operating expense2221
Selling / general / administrative2221
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income6811
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax262141200125
Income after tax262141200125
Income tax, total--000
Net income262141200125
Total adjustments to net income--------
Net income before extra. items262141200125
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items262141200125
Inc. avail. to common incl. extra. items262141200125
Diluted net income262141200125
Dilution adjustment--------
Diluted weighted average shares23202327
Diluted EPS excluding extraordinary itemsvalue per share11.217.028.674.61
Dividends per sharevalue per share0.350.310.040.03
Diluted normalized EPSvalue per share11.217.028.674.61